PXD050857-1

PXD050857 is an original dataset announced via ProteomeXchange.

Title	The use of omics technologies in creating LBP and postbiotics based on the Limosilactobacillus fermentum U-21
Description	In recent years, there has been an increasing tendency to create drugs of various types based on certain commensal bacteria of the human microbiota and their ingredients. This primarily concerns live biotherapeutics (LBPs) and postbiotics. The creation of such drugs, which can be called pharmacobiotics, requires an understanding of the mechanisms of their action and the identification of pharmacologically active ingredients that determine their target properties. As a rule, this is a complex of biologically active substances synthesized by a specific strain, promoted as LBP or postbiotics (including vesicles): proteins, enzymes, low molecular weight metabolites, small RNAs, etc. In this article, we, primarily targeting neuroinflammatory processes, explore the potential of omics technologies, including genomics, proteomics, transcriptomics, and metabolomics, in harnessing the potential of Limosilactobacillus fermentum U-21 for the development of innovative LBP and postbiotic formulations. Metabolomics and proteomics were employed to elucidate the underlying mechanisms governing the unique attributes of L.fermentum U-21, with particular emphasis on the potential for utilizing its vesicles in postbiotic production. This study utilizes cutting-edge proteomic techniques to identify and quantify the proteins expressed, shedding light on their functional attributes and potential applications. Furthermore, metabolomic analysis provides valuable insights into the small-molecule metabolites produced during fermentation, which made it possible to detect compounds with anti-neuroinflammatory activity. As a result, metabolites and proteins potentially responsible for the immunomodulatory, anti-neuroinflammatory and neuromodulatory activities that were detected in the strain in previous experiments, were identified, including in vesicles. We have shown that L.fermentum U-21 is capable of synthesizing: GABA, Niacin, cyclo(Leu-Gly), Aucubin, chaperone proteins with potential disaggregase activity, and the chemical chaperone scyllo-inositol.
HostingRepository	PRIDE
AnnounceDate	2024-06-04
AnnouncementXML	Submission_2024-06-04_08:24:16.925.xml
DigitalObjectIdentifier
ReviewLevel	Peer-reviewed dataset
DatasetOrigin	Original dataset
RepositorySupport	Unsupported dataset by repository
PrimarySubmitter	Olga Tikhonova
SpeciesList	scientific name: Limosilactobacillus fermentum; NCBI TaxID: 1613;
ModificationList	acetylated residue; monohydroxylated residue; iodoacetamide derivatized residue
Instrument	Q Exactive HF

Revision	Datetime	Status	ChangeLog Entry
0	2024-03-21 05:09:40	ID requested
⏵ 1	2024-06-04 08:24:17	announced
2	2024-10-22 06:43:46	announced	2024-10-22: Updated project metadata.

Dataset with its publication pending

submitter keyword: pharmabiotics, metabolome, omics technologies, Limosilactobacillus fermentum U-21, proteome, postbiotics

Olga V. Tikhonova
contact affiliation	Institute of Biomedical Chemistry
contact email	ovt.facility@gmail.com
lab head
Olga Tikhonova
contact affiliation	Institute of Biomedical Chemistry
contact email	ovt.facility@gmail.com
dataset submitter

Dataset FTP location NOTE: Most web browsers have now discontinued native support for FTP access within the browser window. But you can usually install another FTP app (we recommend FileZilla) and configure your browser to launch the external application when you click on this FTP link. Or otherwise, launch an app that supports FTP (like FileZilla) and use this address: ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2024/06/PXD050857

PRIDE project URI

• PRIDE
  1. PXD050857
     1. Label: PRIDE project
     2. Name: The use of omics technologies in creating LBP and postbiotics based on the Limosilactobacillus fermentum U-21